Home › Cancro (tutti i tipi) › Michigan › Detroit
Studi clinici su Cancro (tutti i tipi) a Detroit, MI
29 studi su Cancro (tutti i tipi) cercano partecipanti presso sedi a Detroit e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
In reclutamentoFase 3
- Barbara Ann Karmanos Cancer Center, Detroit
- Henry Ford Cancer Institute-Henry Ford Hospital, Detroit
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
In reclutamentoFase 3
- Karmanos Cancer Center ( Site 0108), Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
In reclutamentoFase 2
- Henry Ford Health Saint John Hospital, Detroit
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
In reclutamentoFase 2/3
- Karmanos Cancer Center Wayne State University, Detroit
Connect for Cancer Prevention Study (Connect)
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Henry Ford Health Systems, Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
In reclutamentoFase 1/2
- GSK Investigational Site, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
In reclutamentoFase 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
In reclutamentoFase 1/2
- Henry Ford Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
In reclutamentoStudio osservazionale
- Karmanos Cancer Institute, Detroit
Project: Every Child for Younger Patients With Cancer
In reclutamentoStudio osservazionale
- Children's Hospital of Michigan, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Karmanos Cancer Institute, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- Henry Ford Health Saint John Hospital, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
In reclutamentoFase 1
- Henry Ford Hospital, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Henry Ford Hospital, Detroit
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
In reclutamentoFase 2
- Karmanos Cancer Center (Wayne State University), Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
In reclutamentoFase 1/2
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
In reclutamentoFase 1
- GSK Investigational Site, Detroit
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
In reclutamentoFase 1
- GSK Investigational Site, Detroit
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
In reclutamentoFase 1/2
- Karmanos Cancer Institute, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
In reclutamentoFase 1
- Henry Ford Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
In reclutamentoFase 1/2
- Henry Ford Health, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
In reclutamentoFase 1
- Karmanos Cancer Institute, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
In reclutamento
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
In reclutamentoFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
In reclutamentoFase 1/2
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
In reclutamentoStudio osservazionale
- Henry Ford Health System, Detroit
Studi su Cancro (tutti i tipi) in altre città
- Houston, TX121 studi
- New York City, NY109 studi
- Boston, MA85 studi
- Los Angeles, CA74 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Washington, DC58 studi
- Durham, NC58 studi
- Chicago, IL51 studi
- Atlanta, GA49 studi
- Seattle, WA49 studi
- Arlington, VA48 studi
Altri studi a Detroit
- Cancro del polmone non a piccole cellule44 studi
- Cancro al seno33 studi
- Cancro colorettale26 studi
- Cancro ovarico26 studi
- Cancro metastatico24 studi
- Cancro alla prostata22 studi
- Cancro dell'endometrio21 studi
- Cancro ai polmoni20 studi
- Mieloma multiplo19 studi
- Cancro dello stomaco16 studi
- Carcinoma a cellule squamose della testa e del collo15 studi
- Leucemia mieloide acuta14 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.